Aptahem AB (publ) (NGM:APTA)

Sweden · Delayed Price · Currency is SEK

0.640

+0.020 (3.23%)

At close: Apr 27, 2026

-56.90% (1Y)

Market Cap	13.42M
Revenue (ttm)	2.59M
Net Income (ttm)	-6.49M
Shares Out	20.97M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	98,866
Average Volume	56,639
Open	0.620
Previous Close	0.620
Day's Range	0.606 - 0.736
52-Week Range	0.500 - 2.400
Beta	0.45
RSI	42.60
Earnings Date	May 15, 2026

About Aptahem AB

Aptahem AB (publ), a biotechnology company, engages in the development of ribonucleic acid-based pharmaceuticals in Sweden. The company’s lead product candidate is Apta-1, which is in Phase I clinical trial for the treatment of patients with sepsis/septic shock and severe inflammatory conditions, as well as to prevent organ and tissue damages in life-threatening conditions. It also develops Apta-2 which is in preclinical stage for the treatment of inflammation; and Apta-3 which is in discovery stage. The company has a collaboration with Hongene... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2014

Employees 3

Stock Exchange Nordic Growth Market

Ticker Symbol APTA

Full Company Profile

Financial Performance

In 2025, Aptahem AB's revenue was 2.59 million, a decrease of -32.73% compared to the previous year's 3.84 million. Losses were -6.49 million, -24.58% less than in 2024.

Financial Statements

News

Aptahem AB Transcript: Status Update

A lead RNA aptamer for sepsis is advancing toward phase 2, with strong preclinical and phase 1 data. U.S. listing preparations are underway to access better valuation and regulatory incentives, while partnerships and expanded IP are being pursued for broader impact.

6 months ago - Transcripts